ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 128 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $198,925 | +4.1% | 202,985 | +394.4% | 0.00% | – |
| Q1 2022 | $191,000 | -43.8% | 41,059 | +281.1% | 0.00% | -100.0% |
| Q1 2020 | $340,000 | +49.1% | 10,774 | +73.3% | 0.00% | – |
| Q3 2019 | $228,000 | -49.1% | 6,216 | -45.7% | 0.00% | – |
| Q2 2018 | $448,000 | -90.2% | 11,442 | -81.9% | 0.00% | -100.0% |
| Q1 2018 | $4,581,000 | +174.1% | 63,336 | +149.6% | 0.01% | +150.0% |
| Q4 2017 | $1,671,000 | -67.9% | 25,380 | -75.5% | 0.00% | -66.7% |
| Q3 2017 | $5,199,000 | +282.0% | 103,726 | +252.7% | 0.01% | +200.0% |
| Q2 2017 | $1,361,000 | -4.1% | 29,407 | -51.1% | 0.00% | -33.3% |
| Q3 2015 | $1,419,000 | -77.3% | 60,167 | -21.1% | 0.00% | -75.0% |
| Q2 2015 | $6,238,000 | -0.9% | 76,296 | +12.2% | 0.01% | -14.3% |
| Q1 2015 | $6,297,000 | +1187.7% | 68,000 | +462.0% | 0.01% | +1300.0% |
| Q4 2014 | $489,000 | – | 12,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |